Treatment of Cystoid Macular Edema With Oral Acetazolamide in a Patient With Best Vitelliform Macular Dystrophy

Optical Coherence Tomography Analysis of Cystoid Macular Edema in Retinal Dystrophy Treated with Oral Acetazolamide: Two Cases

“…Iannaccone et al [7] used 125 mg of oral AZM per day for 12 weeks, followed by a reduced dose of 62.5 mg combined with topical CAI, which was effective during the 2 years of follow-up. Similarly, Hori et al [8] used the same dos-age as ours, 250 mg daily, and reported visual stability for 6 years, disrupted only by a period of recurrence when AZM was temporarily stopped by the patient. Our patients have only been followed for a short period of time, thus a clear conclusion regarding treatment dosage and duration cannot be deduced.…”

“…Contrarily, Iannaccone et al [7] suggested that schisis and cystoid macular edema can be improved by oral CAIs as it happened in our case. Reports concerning BVMD are even less, with Hori et al [8] presenting a case where AZM had a positive effect on cystoid macular edema in a young female.…”

“…In ESCRS, approaches are limited, as one report has suggested laser photocoagulation and another one oral and topical CAIs for the management of macular edema related to retinoschisis [6,7]. In BVMD, multiple approaches have been proposed regarding choroidal neovascularization, but only one report focuses on macular edema without neovascularization, suggesting oral CAIs [8].…”

Choroidal neovascularisation secondary to Best’s disease in a 13-year-old boy treated by intravitreal bevacizumab

“…There are no evidence-based treatment options available to date; however, photodynamic therapy and argon laser photocoagulation have been reported to be an effective treatment option in case reports [2,3]. Oral acetazolamide may reduce cystoid macular edema [4]. We report a rare case of CNV secondary to Best's disease in childhood treated by an intravitreal injection of bevacizumab.…”

Hydrophobic Substituents of the Phenylmethylsulfamide Moiety Can Be Used for the Development of New Selective Carbonic Anhydrase Inhibitors

“…Indeed, a wealth of derivatives, mainly containing a primary sulfonamide (RSO 2 NH 2 ) [1, 2, 4–6] and its bioisosteres, such as the sulfamate (ROSO 2 NH 2 ) [1, 7, 8] and sulfamide (RNHSO 2 NH 2 ) [1, 2, 9–18] as zinc anchoring groups, have been investigated as CA inhibitors (CAIs) with some of them (principally sulfonamides and sulfamates) being explored for the treatment of a variety of disorders such as glaucoma [19–22], acid-base disequilibria [23], epilepsy [24, 25] neuromuscular diseases [26], edema [27], and obesity [28, 29] and for the management of hypoxic tumors [30]. Acetazolamide (AAZ) 1 [31], methazolamide (MZA) 2 [31], topiramate (TPM) 3 [32], ethoxzolamide (EZA) 4 [33], and dichlorphenamide (DCP) 5 [31] represent some examples of such pharmacologically relevant CAIs (Figure 1).…”